Press Releases May 28, 2026 08:30 AM

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics to Engage with Investors at Jefferies 2026 Global Healthcare Conference

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference where its CEO and leadership will present via a fireside chat and webcast. The event aims to communicate the company's progress and future plans to investors.

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
ACRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aclaris Therapeutics will participate in a high-profile healthcare conference, signaling investor engagement.
  • The company is focused on developing novel treatments for immuno-inflammatory diseases.
  • A live webcast will allow broader access to the leadership's discussion, potentially enhancing transparency and investor confidence.

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Risks

  • As a clinical-stage biopharmaceutical company, product candidates are still in development and not yet commercialized, which carries inherent clinical and regulatory risks.
  • Market reception depends on the progress and success of the company’s R&D pipeline, which can be uncertain.
  • Broader economic or sector-specific market volatility may affect investor sentiment despite the company's engagement activities.

More from Press Releases

Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 11, 2026 EverCommerce Announces an Increase and Extension of its Share Repurchase Program Sep 11, 2026 Grupo Aeroportuario del Pacifico Announces the Execution of Bank Credit Facilities Totaling Ps. 8,000 Million Sep 11, 2026 Eastern International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 11, 2026 ArrowMark Financial Corp. Announces Q2 Results and Special Distribution of $0.10 and Monthly Cash Distribution of $0.15 per Share for September 2026 Sep 11, 2026